Managing skin toxicities related to panitumumab - 17/09/14
, Tara Walton, MPH c, Ryan Del Bel, MMath d, Jack T. Seki, PharmD e, Ava Rafii, BPharm a, Wei Xu, PhD d, Gideon Koren, MD a, Neil Shear, MD g, Monika K. Krzyzanowska, MD, MPH b, c, f, Doris Howell, PhD c, Geoffrey Liu, MD, MSc b, c, fAbstract |
Background |
Dermatologic toxicities from targeted agents such as panitumumab can interfere with cancer treatment.
Objective |
We sought to evaluate the rash assessment and management in a consecutive patient cohort who received panitumumab for colorectal cancer treatment.
Methods |
This was a retrospective chart review.
Results |
Skin toxicity, consisting of papulopustular rash, was experienced by 32 of 34 patients. The majority (85%) developed the rash by the end of the second infusion cycle. Patients presented with a mild (41%), moderate (38%), and severe (21%) rash, and progressed to an extensive rash without appropriate treatment. A grading system was used for 65% of patients to document severity.
Limitations |
Small sample size limited power in analysis. Rash severity had to be inferred based on rash description and management in 11 of the patients.
Conclusion |
Dermatologic toxicities related to panitumumab are common; however, the way they are reported and managed varies among physicians. To prevent progression, toxicities must be assessed and treated early and aggressively, according to severity grading. Dermatologists could aid oncologists in choosing the best management strategies.
Le texte complet de cet article est disponible en PDF.Key words : Common Toxicity Criteria for Adverse Events, epidermal growth factor receptor inhibitors, panitumumab, papulopustular rash, skin toxicity
Abbreviations used : CTCAE, EGFR, PMCC
Plan
| Supported by Cancer Care Ontario and Ontario Patient-Reported Outcomes of Symptoms and Toxicity. Dr Liu is supported by the Alan B. Brown Chair in Molecular Genomics and the Posluns Family Fund. Dr Howell is supported by the Royal Bank of Canada (RBC) Chair in Oncology Nursing Research. |
|
| Conflicts of interest: None declared. |
Vol 71 - N° 4
P. 754-759 - octobre 2014 Retour au numéro
Article précédent
- Graft-versus-host disease-associated angiomatosis: A clinicopathologically distinct entity
- Benjamin H. Kaffenberger, Rena C. Zuo, Alejandro Gru, Alisha N. Plotner, Sarah A. Sweeney, Steven M. Devine, Sharon R. Hymes, Edward W. Cowen
- Reliability of Clinician Erythema Assessment grading scale
- Jerry Tan, Hong Liu, James J. Leyden, Matthew J. Leoni
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?